Shares of MEDNAX Inc (NYSE:MD) have received an average rating of “Hold” from the sixteen ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $51.75.
Several analysts recently weighed in on MD shares. Leerink Swann upgraded MEDNAX from a “market perform” rating to an “outperform” rating in a report on Monday, September 24th. Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. Robert W. Baird lowered their price objective on MEDNAX from $50.00 to $48.00 and set a “neutral” rating on the stock in a research note on Friday, October 19th. ValuEngine raised MEDNAX from a “strong sell” rating to a “sell” rating in a research note on Friday, August 3rd. Finally, Credit Suisse Group raised MEDNAX from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $47.00 to $55.00 in a research note on Friday, August 3rd.
In other MEDNAX news, insider John C. Pepia sold 3,500 shares of MEDNAX stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $48.18, for a total value of $168,630.00. Following the sale, the insider now owns 30,148 shares in the company, valued at $1,452,530.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by insiders.
Shares of MD traded up $0.06 during trading hours on Friday, hitting $40.53. The company had a trading volume of 26,356 shares, compared to its average volume of 1,151,714. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.43 and a quick ratio of 1.43. The firm has a market cap of $3.53 billion, a PE ratio of 12.87, a P/E/G ratio of 1.05 and a beta of 0.33. MEDNAX has a 52-week low of $37.26 and a 52-week high of $63.04.
MEDNAX (NYSE:MD) last issued its earnings results on Thursday, November 1st. The company reported $0.94 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.97 by ($0.03). MEDNAX had a return on equity of 10.45% and a net margin of 9.50%. The business had revenue of $896.60 million during the quarter, compared to analysts’ expectations of $908.15 million. During the same period last year, the firm posted $0.87 EPS. MEDNAX’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that MEDNAX will post 3.57 EPS for the current year.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
See Also: What is a Reverse Stock Split?
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.